Iovance Biotherapeutics Investor Presentation — August 2024

Document content

© 2024, Iovance Biotherapeutics, Inc.

© 2024, Iovance Biotherapeutics, Inc.

© 2024, Iovance Biotherapeutics, Inc.Forward -Looking Statements

Certain matters discussed in this press release are “forward- looking statements” of Iovance Biotherapeutics, Inc. (hereinafter r eferred to as the “Company,” “we,” “us,” or “our”) within the meaning

of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Without limiting the foregoing, we may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,”

“estimates,” “anticipates,” “expects,” “plans,” “intends,” “forecast,” “guidance,” “outlook,” “may,” “can,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events

or outcomes and are intended to identify forward- looking statements. Forward- looking statements are based on assumptions and assessments made in light of management’s experience and

perception of historical trends, current conditions, expected future developments, and other factors believed to be appropria te. Forward- looking statements in this press release are made as of the

date of this press release, and we undertake no duty to update or revise any such statements, whether as a result of new info rma tion, future events or otherwise. Forward- looking statements are not

guarantees of future performance and are subject to risks, uncertainties, and other factors, many of which are outside of our control, that may cause actual results, levels of activity, performance,

achievements, and developments to be materially different from those expressed in or implied by these forward -looking statements . Important factors that could cause actual results, developments,

and business decisions to differ materially from forward -looking statements are described in the sections titled "Risk Factors" in our filings with the U.S. Securities and Exchange Commission,

including our most recent Annual Report on Form 10 -K and Quarterly Reports on Form 10 -Q, and include, but are not limited to, th e following substantial known and unknown risks and uncertainties

inherent in our business: the risks related to our ability to successfully commercialize our products, including Amtagvi, for which we have obtained U.S. Food and Drug Administration (“FDA”)

approval, and Proleukin, for which we have obtained FDA and European Medicines Agency (“EMA”) approval; the risk that the EMA or other ex -U.S. regulatory authorities may not approve or may delay

approval for our marketing authorization application submission for lifileucel in metastatic melanoma; the acceptance by the mar ket of our products, including Amtagvi and Proleukin, and their

potential pricing and/or reimbursement by payors, if approved (in the case of our product candidates), in the U.S. and other int ernational markets and whether such acceptance is sufficient to support